In the aftermath of one of Silicon Valley’s most infamous frauds, the biotech sector finds itself confronting an uncomfortable echo. Elizabeth Holmes—still serving time for the Theranos scandal—is once again adjacent to the world of health innovation. This time, it's through her partner, Billy Evans, who now leads a startup called Haemanthus. On paper, Hemanthus blends legitimate technologies: Raman spectroscopy and deep learning models aimed at fluid-based diagnostics. The i